"Precision Therapy for Advanced Prostate Cancer"
PHEN's December meeting and webcast will feature a presentation by Dr. Philip Kantoff about the Stand Up to Cancer (SU2C) Dream Team project titled "Precision Therapy for Advanced Prostate Cancer." Dr. Kantoff will provide a detailed description of the project and outline opportunities, benefits and requirements for patients to participate.
This project could help identify and better understand any prostate cancer genetic aberrations that might be more common to African American patients and which therapies might work best. PHEN is working with the Dream Team to provide education about the project and to assist in enrolling patients.
Philip W. Kantoff, MD, Dana Farber Cancer Institute;
Chief, Division of Solid Tumor Oncology; Chief Clinical Research Officer; Director, Lank Center for Genitourinary Oncology; Professor of Medicine, Harvard Medical School